Exhibit 10.44


                        RESEARCH COLLABORATION AGREEMENT

This  Agreement  entered into on this  ____day of  __________  2004  ("Effective
Date") by and between DNAPRINT GENOMICS,  INC., a for profit corporation located
at 900  Cocoanut  Avenue,  Sarasota,  FL 34236  ("the  Company")  and the H. LEE
MOFFITT  CANCER  CENTER AND RESEARCH  INSTITUTE,  INC., a Florida not for profit
corporation organized pursuant to Section 1004.43, Florida Statutes,  located at
12902 Magnolia Drive, Tampa,  Florida 33612 ("Moffitt") Company, and Moffitt are
hereinafter each  individually  referred to as a "Party" and collectively as the
"Parties."

         WHEREAS,  the Company is the assignee of all rights, title and interest
in certain  proprietary  mapping  strategy  and  patented  Ancestry  Informative
Markers  and OTHER  PROPRIETARY  TECHNOLOGIES,  TOOL AND  KNOW-HOW  THAT ARE THE
SUBJECT OF VARIOUS PATENT PENDING APPLICATIONS ("COMPANY IP");


         WHEREAS,  Moffitt and the  University  of South  Florida  ("USF")  have
executed a Research Addendum to its Affiliation  Agreement that ensures that USF
provide principal  investigators and other services to Moffitt for Moffitt-based
research and further grants to Moffitt the authority to negotiate and enter into
agreements   respecting  the  protection   and   commercialization   of  certain
Intellectual Property in the name of Moffitt.

         WHEREAS,  the USF and/or Moffitt are the assignees of all rights, title
and interest in certain technology and biological  materials  including patented
and pending patent applications. ("USF/Moffitt IP")

         WHEREAS,  it is in the  mutual  interest  of  Company  and  Moffitt  to
participate and collaborate in certain projects  ("Projects") which are outlined
generally, attached hereto and incorporated by reference as Exhibit A;

         WHEREAS,  the Parties  acknowledge  that  Exhibit A may be amended from
time to time to add additional studies to the Project.

         WHEREAS,  the Company,  and certain Moffitt and/or University employees
which will be  designated  for each  Project  ("Principal  Investigators")  will
collaborate to ensure that each Project is carried out according to the scope of
work set forth for each Project; and

         WHEREAS, the Parties are interested in collaborating with each other to
study methods to determine  responses to anticancer drugs utilizing  specialized
genetic tests.  The Moffitt Labs will use gene expression  techniques  while the
Company Labs will utilize SNP's techniques. --------------

         NOW, THEREFORE, the Parties agree as follows:

1. SCHEDULE The Projects shall be carried out from November 17, 2003 to November
17, 2006 ("Project  Period") unless sooner terminated by written notice pursuant
to Section 10 of this  Agreement.  This Agreement may be renewed by the Parties,
as a new Agreement or by amendments to this Agreement.


<PAGE>

2. PRINCIPAL INVESTIGATORS - The research is to be conducted under the direction
of the Principal Investigators.  It will be the responsibility of each Principal
Investigator to transmit and receive information from the Parties, to coordinate
visits and arrange all other matters pertinent to the Project.

3. FUNDING - Neither Party is obligated to fund the research of the other Party.
Hence,  Company and Moffitt  shall each be  responsible  for their own  expenses
incurred in the  performance  of the  Projects,  unless  otherwise  agreed to in
writing.  Moffitt  makes no  representations  that they  will fund any  clinical
trials that may ensue from the Projects. Funding for the clinical trials will be
dependent upon each Principal Investigator's ability to financially support such
trials and or support from Company or another third party.

4.  CONFIDENTIALITY  - Except as expressly  set forth herein,  any  confidential
information exchanged by the Parties shall be held in confidence  ("Confidential
Information").  The Parties  agree that for a period of three (3) years from the
expiration or termination of this Agreement,  all  information  exchanged by the
parties and marked as Confidential  and oral  disclosures that have been reduced
to writing within thirty (30) days of the disclosure and marked as  Confidential
shall be covered by this Agreement.  The Parties further agree that for a period
of three  (3)  years  after  the  termination  of this  Agreement,  Confidential
Information  from either Party will be maintained  in  confidence  with the same
degree of care that they employ with respect to their own information.  However,
neither  Party  shall  have  any   obligation   with  respect  to   Confidential
Information, which is:

         (i)  independently  developed  by the  receiving  Party as evidenced by
         written records,  without the benefit of the disclosure,  or is already
         known to the receiving Party at the time of disclosure;

         (ii) publicly known or becomes  publicly known without the wrongful act
         or breach of this Agreement by the receiving Party;

         (iii) rightfully  received by the receiving Party from a third party on
         a non-confidential basis; or

         (iv) is required to be disclosed by law or court order.

4.1 Any  combination  of  features  or  disclosures  shall not be deemed to fall
within the foregoing exclusions merely because individual features are published
or available to the general  public or in the  rightful  possession  of a Party,
unless the  combination  itself and  principle  of  operation  are  published or
available to the general public or in the rightful possession of such Party.

5.  RESEARCH  REPORTS  AND  PUBLICATION  Each Party  shall  promptly,  fully and
confidentially inform the other Parties of the results of the research conducted
hereunder.  Company  and  Moffitt  will  consult on  mutually  agreed  times and
intervals regarding the progress of the Project.

5.1 Each Party  reserves  the right to publish  information  resulting  from the
Projects.  The Parties may jointly publish  information  related to the Projects
with authorship  determined by the usual academic standards.  Moffitt and/or USF

<PAGE>

shall have the right to use any facts,  findings or other  research  information
resulting  from the Project for  research and  educational  purposes  only.  The
Parties  agree that they shall  give each  other the  opportunity  to review any
proposed  manuscript  thirty (30) days prior to submission  for  publication  in
order  that   Confidential   Information  if  any,  may  be  removed  or  patent
applications may be timely filed.

6. PUBLICITY None of the Parties shall use the name of another Party in any form
of advertising or promotion without the prior written approval of the other. The
Parties  may  however,  acknowledge  each  other's  support in  matters  such as
publications.  In any such  statement,  the  relationship  of  Parties  shall be
accurately and appropriately described.

7. PATENT RIGHTS It is recognized and understood that the Parties are engaged in
proprietary  research and  development  activities.  Both Parties have rights to
their own separate  intellectual  property,  and may further have  materials and
technologies    that   are   the    subject    of   various    patent    pending
applications,("Background  Technology") which are not affected by this Agreement
or by any  Amendment  to this  Agreement.  This  Agreement in no way confers any
license  under any patent or  proprietary  interests  of one Party's  Background
Technology to the other Party

7.1 Title to all inventions and  discoveries  conceived  and/or first reduced to
practice solely by Company as a result of these Projects,  shall reside with the
Company.  Title to all inventions and discoveries conceived and/or first reduced
to practice  solely by Moffitt  and/or USF shall reside with Moffitt and/or USF.
USF and/or  Moffitt and Company  shall jointly own title to all  inventions  and
discoveries  made,  conceived  and/or reduced to practice jointly by the Parties
resulting  from  these  Projects  ("Joint  Inventions").  All  Parties  agree to
immediately  notify each other in the event an invention  is made.  Inventorship
shall  be   determined   in   accordance   with  United   States   Patent  Laws.
Notwithstanding  any  provision  herein to the contrary,  intellectual  property
rights between Moffitt and University shall be governed by the Research Addendum
signed on September 24, 2003.

7.2 The Parties  agree that it is in their best  interest to  commercialize  any
Joint Inventions resulting form the Projects. In the event that Joint Inventions
are commercialized, the Parties agree

7.3 Except for the  granting of rights to  respective  governmental  agencies as
required by law and the offer of Terms made in this Section 7, the Parties agree
that  during  the term of this  agreement  neither  party  will  issue a license
agreement or assign patent rights to any third parties without the prior written
consent of the other Parties.

8. EXCHANGES OF MATERIALS AND DATA All materials including progeny of biological
materials and data  exchanged  pursuant to the Project shall remain the property
of the  providing  Party,  and shall be used  solely  for the  purposes  of this
Agreement.  Upon  termination of this  Agreement,  the rights granted under this
Agreement to each other to use the materials and data of each Party by the other
Party shall terminate immediately.  The unused portions of the materials will be
returned  to the  providing  Party or will be  disposed  of as  directed  by the
providing Party in writing.  If a Party desires to use Material  exchanged under
this Agreement for research other than the Project, it will obtain prior written

<PAGE>

consent  from the  other  Party,  or  Parties,  by way of an  amendment  to this
Agreement or by way of a new Agreement.

8.1  Material  exchanged  under this  Agreement  is being  supplied to the other
Parties  with no  warranties,  expressed or implied,  including  any warranty of
merchantability  or  fitness  for  a  particular  purpose.   Provider  makes  no
representations  that the use of the  Research  Material  will not  infringe any
patent or any proprietary  rights of third parties.  Recipients  agree to assume
all  liability  for damages that arise from the use,  storage or disposal of the
Material.

8.2 The Material is for use only by each Party and is NOT FOR USE IN HUMANS.  No
specimens of the Material are to be given or made  available to any other person
other than the other  Party's  employees,  and are to remain  under each Party's
immediate and direct control.

8.3 All Parties assure that any Material  exchanged under this Agreement will be
handled safely and labeled,  packaged,  and  transported in accordance  with all
applicable laws and regulations.

9.0 REPRESENTION AND WARRRANIES: The parties represent and warrant that they are
legally  able to enter  into  this  Agreement  and are under no  obligations  to
acquire approval of any other person or entity to enter into this Agreement.

10.0  INDEPENDENT  CONTRACTOR:  Company  agrees  that for the  purposes  of this
Agreement all services to be provided hereunder, the parties shall be, and shall
be deemed to be,  independent  contractors  and not agents or  employees  of the
other  party.  Neither  party  shall  have  authority  to make  any  statements,
representations or commitments of any kind, or to take any action which shall be
binding on the other party,  except as may be  expressly  provided for herein or
authorized in writing

10.1  Company  shall  maintain  adequate  insurance  for the  protection  of its
personnel  housed at Moffitt.  The level of  insurance is set forth in Exhibit B
attached to this Agreement and incorporated by reference.

10.2 Company agrees that Moffitt shall not be liable for the injuries  caused by
Company's  employees  while  house at  Moffitt  except to the  extent  that such
injuries were caused by negligent acts or negligent  omissions of Moffitt or its
employees.

10.3  Notwithstanding  any  thing to the  contrary,  Moffitt  shall not have any
liability to Company for any claim of loss of profits,  loss of  interruption of
business, or for indirect, special or consequencial damages of any kind.

10.4  Company  agrees  that  should any such  injury  occur that  Company  shall
immediately notify Moffitt pursuant to Paragraph 12, Notices.


11.  NOTICE -  Whenever  any  notice  is to be given  hereunder,  it shall be in
writing and sent to the following address:

<PAGE>

COMPANY:                            Richard Gabriel
                                    ---------------------------
                                    President & CEO
                                    DNAPrint genomics, Inc.
                                    900 Coconut Avenue
                                    Sarasota, FL 34236


Moffitt:                            Director of Technology Transfer
                                    H. Lee Moffitt Cancer Center
                                      and Research Institute, Inc.
                                    12902 Magnolia Drive
                                    Tampa, Florida  33612-9497


         Any Party may change its  address by  providing  written  notice to the
other Parties.

12.  TERMINATION  This Agreement may be terminated by any Party at any time upon
the  giving  of ninety  (90) days  prior  written  notice to the other  Parties.
Written notice shall be directed to the appropriate  individual named in Article
11 ("NOTICE") of this Agreement.

         If a Party materially  breaches a material provision of this Agreement,
         the other  party may  terminate  this  Agreement  upon 30 days'  notice
         unless the breach is cured within the notice period.

         Articles 4 through 9 shall survive termination of this agreement

13.  GOVERNING LAW The  construction  and  performance of this Agreement will be
governed by the laws of the State of Florida.  Venue for any action  arising out
of this Agreement or the  relationship  of the Parties shall be in  Hillsborough
County, Florida.

14. COST OF ENFORCEMENT.  If either party engages an attorney or any other third
party or in any way  initiates  legal  action to enforce  its rights  under this
Agreement,  the  nonprevailing  party agrees to pay to the prevailing  party all
costs and expenses  incurred by it relating to the enforcement of this Agreement
(including reasonable attorneys' and legal assistants' fees before, at and after
trial and in appellate proceedings).

15. AMENDMENTS. Any amendment additions or supplement to this Agreement shall be
effective  and binding on Moffitt and Company only if done in writing and signed
by authorized parties at Moffitt and Company.



                             SIGNATURE PAGE FOLLOWS.

<PAGE>

DNAPRINT GENOMICS, INC.                 THE H. LEE MOFFITT CANCER CENTER AND
                                          RESEARCH INSTITUTE, INC.


By:                                     By:
    -----------------------------           ---------------------------------

Name:                                   Name: James J. Mule
     ----------------------------             Associate Center Director,
                                              Translational Science and
                                              Technology Development

Title:                                  Title:
      ---------------------------              ------------------------------

Date:                                   Date:
      ---------------------------             -------------------------------


<PAGE>

                                    EXHIBIT A

                                PROPOSED STUDIES

DNAPRINT GENOMICS, INC. AND THE H. LEE MOFFITT CANCER CENTER RESEARCH INSTITUTE,
                    INC. AT THE UNIVERSITY OF SOUTH FLORIDA.

                                      GOALS


BACKGROUND

THE H. LEE MOFFITT CANCER CENTER

The H. Lee Moffitt Cancer Center - has a substantial program involved in cancer,
has access to a l85,000 patient clinical center and has expertise in the conduct
of clinical trials.

DNAPRINT  GENOMICS,  INC.  -  IS A  PHARMACOGENOMICS  COMPANY  WITH  PROPRIETARY
TECHNOLOGIES TO STUDY DNA SAMPLES AND DETERMINE CLASSIFIERS TO PREDICT RESPONSES
TO DRUGS.


STUDY PROPOSAL ON COLON CANCER
PRINCIPAL INVESTIGATOR AT MOFFITT:  TIM YEATMAN, MD_____________________________

STUDY PROPOSAL ON MULTIPLE MYELOMA
PRINCIPAL INVESTIGATOR AT MOFFITT: DANIEL SULLIVAN, MD__________________________


STUDY PROPOSAL ON CYCLOPHOSPHAMIDE
PRINCIPAL INVESTIGATOR AT MOFFITT: RICHARD M. LUSH, PHD_________________________


STUDY PROPOSAL ON TAXANES
PRINCIPAL INVESTIGATOR AT MOFFITT: JONATHAN M. LANCASTER, MD